A Prospective Study to Evaluate Biochemical Alterations to Assess the Severity of Dengue Fever in Adults in Coimbatore Medical College and Hospital, Coimbatore by Vasanthan, M
A Dissertation on 
A PROSPECTIVE STUDY TO EVALUATE  BIOCHEMICAL   
ALTERATIONS TO ASSESS THE SEVERITY OF DENGUE 
FEVER IN ADULTS IN CMC HOSPITAL 
 
 
 
 
 
 
Dissertation Submitted to 
 
THE TAMILNADU Dr.M.G.R. MEDICAL 
UNIVERSITY CHENNAI - 600 032 
 
With partial fulfillment of the 
regulations for the award of the 
degree of 
 
M.D. GENERAL MEDICINE BRANCH-I 
 
 
 
 
 
 
 
 
COIMBATORE MEDICAL COLLEGE, COIMBATORE 
 
MAY 2019 
CERTIFICATE 
 
 
Certified that, this is the bonafide dissertation done by Dr.M.VASANTHAN 
and submitted in partial fulfilment of the  requirements for the Degree of M.D., 
General Medicine, Branch I of The Tamilnadu DR. M.G.R. Medical University 
Chennai. 
 
 
 
 
 
Date:                                                                     Guide & Professor  VIth  Unit 
                                                                              Dr.K.SWAMINATHAN.,M.D 
 
 
 
 
 
 
 
 
Date:                                                                  HOD & Professor 
Dr.KUMAR NATARAJAN.,M.D 
Department of Medicine 
 
 
 
 
 
 
 
 
 
 
 
Date                                                                   DEAN 
Dr. B.ASOKAN,M.S,Mch 
Coimbatore Medical College 
Coimbatore 
 
  
CERTIFICATE - II 
This is to certify that this dissertation work titled “A PROSPECTIVE STUDY TO 
EVALUATE  BIOCHEMICAL  ALTERATIONS TO ASSESS THE SEVERITY 
OF DENGUE FEVER IN ADULTS IN CMC HOSPITAL of the candidate                     
Dr. VASANTHAN M with registration Number  201611316  for the award of  
DOCTOR OF MEDICINE in the branch of GENERAL MEDICINE. I personally 
verified the urkund.com website for the purpose of plagiarism Check. I found that the 
uploaded thesis file contains from introduction to conclusion pages and result shows 
7% percentage of plagiarism in the dissertation. 
 
 
 
 
Guide & Supervisor sign with Seal. 
  
   
   
DECLARATION 
 
I solemnly declare that the dissertation titled “A PROSPECTIVE STUDY    TO 
EVALUATE  BIOCHEMICAL   ALTERATIONS TO ASSESS THE SEVERITY OF 
DENGUE FEVER IN ADULTS IN CMC HOSPITAL ” was done by me from JULY 
2017 to JUNE 2018 under the guidance and supervision of                                                 
Prof. K.SWAMINATHAN, M.D. This dissertation is submitted to The Tamilnadu                             
Dr. M.G.R. Medical University towards the partial fulfilment of the requirement for 
the award of MD Degree in General Medicine (Branch I) 
 
 
 
 
 
 
. 
Date:                                                                  DR.M.VASANTHAN 
Place: 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
I wish to express my sincere thanks to our respected Dean Prof.                                       
Dr. B.ASOKAN,M.S,Mch (Plastic Surgery) for having allowed me to conduct this 
study in our hospital. 
I express my heartfelt thanks and deep gratitude to the Head of the Department 
of Medicine Prof. Dr. KUMAR NATARAJAN, M.D. for his generous help and 
guidance in the course of the study. 
I sincerely thank Prof.DR.K.SWAMINATHAN.M.D, for the valuable help 
and cooperation and allowing me to use institutional facilities. 
I am extremely grateful to Prof.Dr.MANIMEGALAI, M.D (Bio), HOD, 
Department of Biochemistry, for their valuable help and cooperation and allowing me 
to use institutional facilities. 
 I sincerely thank my Assistant Professors- Dr.A.AKIILA. DCH ,M.D, 
Dr.M.BABU, M.D, for their guidance and kind help. 
I express my sincere thanks to all my friends and post-graduate colleagues for 
their whole hearted support and companionship during my studies. 
I thank all my PATIENTS, who formed the backbone of this    study without 
whom this study would not have been possible. 
Lastly, I am ever grateful to the ALMIGHTY GOD for always showering their 
blessings on me and my family 
 
Dr.M.VASANTHAN. 
TABLE OF CONTENTS 
 
 
 
 
  
S.No TITLE PAGE NO 
1. Introduction 1 
   
2. Objectives 3 
   
3. Review of Literature 4 
   
4. Methodology 41 
   
5. Results and Observations 43 
   
6. Discussion 73 
   
7. Summary 76 
   
8. Conclusion 78 
   
9. Limitations of the Study 79 
   
10. Bibliography  
   
11. Annexures  
   
LIST OF ANNEXURES 
 
 
Annexures Title 
  
1 Proforma 
  
2 Consent 
  
3 Key to Master Chart  
  
4 Master chart 
  
 
  
LIST OF TABLES 
SL.NO TABLES PAGE NO 
3.1 
Approximate number of Dengue cases & Death 
reported in 2012 
16 
5.1 Age distribution of study subjects 43 
5.2 Age distribution with types of dengue 44 
5.3 Distribution of study subjects according to sex 45 
5.4 Sex distribution with types of dengue 46 
5.5 Time duration of fever at the time of admission 47 
5.6 
Time duration of fever at the time of admission  with 
types of dengue 
48 
5.7 
Serum Lactate Dehydrogenase levels in dengue 
patients 
49 
5.8 
Analysis of Lactate dehydrogenase levels  with types 
of dengue 
50 
5.9 Serum Creatinine kinase levels in dengue patients 51 
5.10 
Analysis of Creatinie kinase  levels  with types of 
dengue 
52 
5.11 Serum Total cholesterol  levels  in dengue patients 53 
5.12 
Analysis of Total cholesterol  levels  with types of 
dengue 
54 
5.13 Serum High Density Lipoprotein in dengue patients 55 
5.14 
Analysis of High density lipoproteins levels  with 
types of dengue 
56 
5.15 Serum Triglycerides in dengue patients. 57 
5.16 Analysis of Serum Triglycerides with types of dengue 58 
5.17 
Serum SGOT(Aspartate transaminase) in dengue 
patients 
59 
5.18 
Analysis of SGOT(Aspartate transaminase) with 
types of dengue 
60 
5.19 
Serum SGPT(Alanine transaminase) in dengue 
patients. 
61 
5.20 
Analysis of SGPT(Alanine transaminase) with types 
of dengue 
62 
5.21 Serum Serum Albumin in dengue patients 63 
5.22 Analysis of Serum Albumin  with types of dengue 64 
5.23 Number of dengue patients according to types 65 
5.24 
Presence or absence of complications in dengue 
patients 
66 
5.25 
Analysis of Presence or absence of complications 
with types of dengue 
67 
5.26 Blood transfusions given  in dengue patients. 68 
5.27 
Analysis of Blood Transfusions given with types of 
dengue 
69 
5.28 Numbers of death  in dengue patients 70 
5.29 Analysis of Number of deaths  with types of dengue 71 
5.30 Causes of death in dengue patients 72 
 
 
 
 
 
 
 
 
 
LIST OF CHARTS 
SL.NO CHARTS PAGE NO 
5.1 Age distribution of study subjects 43 
5.2 Age distribution with types of dengue 44 
5.3 Distribution of study subjects according to sex 45 
5.4 Sex distribution with types of dengue 46 
5.5 Time duration of fever at the time of admission 47 
5.6 
Time duration of fever at the time of admission  
with types of dengue 
48 
5.7 
Serum Lactate Dehydrogenase levels in dengue 
patients 
49 
5.8 
Analysis of Lactate dehydrogenase levels  with 
types of dengue 
50 
5.9 
Serum Creatinine kinase levels in dengue 
patients 
51 
5.10 
Analysis of Creatinie kinase  levels  with types 
of dengue 
52 
5.11 
Serum Total cholesterol  levels  in dengue 
patients 
53 
5.12 
Analysis of Total cholesterol  levels  with types 
of dengue 
54 
5.13 
Serum High Density Lipoprotein in dengue 
patients 
55 
5.14 
Analysis of High density lipoproteins levels  
with types of dengue 
56 
5.15 Serum Triglycerides in dengue patients. 57 
5.16 
Analysis of Serum Triglycerides with types of 
dengue 
58 
  
5.17 
Serum SGOT(Aspartate transaminase) in 
dengue patients 
59 
5.18 
Analysis of SGOT(Aspartate transaminase) with 
types of dengue 
60 
5.19 
Serum SGPT(Alanine transaminase) in dengue 
patients. 
61 
5.20 
Analysis of SGPT(Alanine transaminase) with 
types of dengue 
62 
5.21 Serum Serum Albumin in dengue patients 63 
5.22 
Analysis of Serum Albumin  with types of 
dengue 
64 
5.23 Number of dengue patients according to types 65 
5.24 
Presence or absence of complications in dengue 
patients 
66 
5.25 
Analysis of Presence or absence of 
complications with types of dengue 
67 
5.26 Blood transfusions given  in dengue patients. 68 
5.27 
Analysis of Blood Transfusions given with types 
of dengue 
69 
5.28 Numbers of death  in dengue patients 70 
5.29 
Analysis of Number of deaths  with types of 
dengue 
71 
5.30 Causes of death in dengue patients 72 
 
LIST OF FIGURES 
SL.NO FIGURES PAGE NO 
3.1 Epidemics in the Southeast Asia regions according to WHO  12 
3.2 Case fatality rate in SEARO regions according to WHO 13 
3.3 Average incidence rate of dengue in India 15 
3.4 
Number of fever and dengue cases at 
Coimbatore medical college from daily 
newspaper “THE HINDU”. 
17 
3.5 Antibody responses to dengue virus 19 
3.6 Different phases of dengue fever 27 
3.7 Classification of dengue fever according to WHO guidelines 31 
3.8 The course of dengue illness 33 
3.9 Larva’s in a container 37 
3.10 Dengue vaccine 39 
 
 
 
 
 
 
 
  
LIST OF ABBREVATIONS 
 
ADE  Antibody Dependent Enhancement 
Alb   Albumin 
ALT   Alanine Transaminase 
AST   Aspartate Transaminase 
CF   Cytotoxic factor 
DF   Dengue Fever 
DHF   Dengue Haemorrhagic Fever 
DSS   Dengue Shock Syndrome 
DNWS         Dengue without warning signs 
DWWS        Dengue with warning signs 
DV   Dengue Virus 
HLA   Human Leucocyte Antigen 
IFN   Interferon 
iNK   Invariant Natural Killer 
IL   Interleukin 
INR   International Normalized Ratio 
IgM   Immunoglobulin M 
NS1   Non Structural protein 1 
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction 
SD  Severe Dengue 
SGOT  Serum Glutamate Oxaloacetate Transaminase 
SGPT  Serum Glutamate Pyruvate Transaminase 
TGF   Transforming Growth Factor 
TNF   Tumor Necrosis Factor 
USG   UltraSonoGram 
WHO  World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
INTRODUCTION 
 
Dengue Fever  is causing many major epidemics in Tamil Nadu for  past 
10 to 20 years, especially very high for past 7 years. Because of this dengue 
fever it puts extra pressure to the government to financially aid to control the 
disease and to supplement  the programme to prevent and to stop the ongoing 
epidemics. 
Increasing world population, and their expansion, unplanned 
urbanisation with poor sanitary management, improper waste water and other 
wastes management and no proper mosquito control measures and no planning 
on their eradication and how to destroy the larva growing in households, with 
increases population and distribution of vector also leads to rapid spread of 
more virulent strains world wide.1 
Dengue fever with unpredictable clinical course ,which is a most 
important vector borne disease which leads to a policy of proper referral from  
peripheral  centers to higher centers  and it is very difficult to predict which 
case will progress to severe dengue with the complications of dengue fever 
.Dengue fever patients have clinical symptoms such as headache, myalgia, 
arthralgia, retroorbital pain, thrombocytopenia, vomiting, skin rash and 
hemorrhagic manifestations-and other features such as  hepatic dysfunction, an 
elevation in serum aminotransferase levels, hepatomegaly , leucopenia, ascites, 
pleural effusion .  
The acute phase of dengue begins with fever that is indifferentiable from the 
initial phase of other acute febrile infectious diseases.2,3,4 It  leads to 
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underestimation of actual incidence, late treatment of a disabling and the 
potentially lethal medical condition. 
With the  direct and indirect evidence of biochemical alterations that are related 
to severity of dengue. Studies had reported that patients with DHF have 
elevated serum levels of transaminases (aspartate aminotransferase [SGOT] 
and alanine aminotransferase [SGPT]),4,5 lactate dehydrogenase (LDH), and 
creatine kinase (CK).7  
Cross-sectional studies have shown decrease in serum levels of cholesterol and 
triglycerides associated with  DHF studies.5 These biochemical markers have 
not been evaluated prospectively in the early stages of dengue. But the utility of 
biochemical alterations that who are more prone to DHF with their timely 
identification  is unknown. In the background of this study with the 
biochemical markers can be able to use as predictors of severity of dengue 
fever.8 
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OBJECTIVES 
 
• In this study the correlation between biochemical alterations and  
progression of probable dengue →dengue with warning signs →Severe dengue 
in adults will be assessed. 
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REVIEW OF LITERATURE 
                          
HISTORY 
 
 From Jin dynasty history of dengue starts, first  it was referred as                  
WATER  POISON thought to be spread by flying insects.9 
 The word “Dengue” has an African origin10,11,12 and derived from the Swahili 
phrase KA-DINGA PEPO which means ―Cramps like seizure. 
 First description of dengue was given by Benjamin Rush in 1780 during an 
epidemic in Philadelphia and coined the term BREAK BONE FEVER.14 
 Mosquito borne transmission of infection by Aedes aegypti was demonstrated 
in 1903 by Graham, by Bancroft in 1906 and by Cleland et al in 1918.15 
 Viral etiology was demonstrated in 1906 by Bancroft. 
 Dengue viral serotypes were discovered in 1944.13 
 Dengue haemorrhagic fever was described after worldwar –II. 
 A disease epidemic attuned with dengue was reported in China as early on as   
992 AD, but the first outbreak of dengue was recorded in 1635 in the French 
West Indies.  
 First epidemic of DHF was reported from patients with haemorrhagic disease 
during an epidemic in Manila in 1956. 
 Sabin and his colleagues showed that virus strains from 3 geographical areas 
like Hawai, New guinea and India were antigenically  similar15. 
 The strain isolated from Hawai was called as DENV-1. 
 Strain isolated from NewGuinea was called as DENV-2 
 DENV-3 & DENV-4 were isolated later on during epidemics in Manila. 
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EPIDEMIOLOGY 
Agent  
The dengue viruses are belong to species Flavivirus & family Flaviviridae. 
These diminutive (50 nm) viruses enclose a single stranded RNA as genome. 
16,17 The virus has four serotypes namely DEN-1, DEN-2, DEN-3, DEN-
4.16,17,18 . There exists considerable genetic variation within each serotype in the 
form of phylogenetically distinct “sub-types” or “genotypes”. Currently, three 
sub-types can be identified for DENV-1, six for  DENV-2 (one of which is 
found in non-human primates), four for DENV-3 and four for DENV-4, with 
another DENV-4 being exclusive to non-human primates. 19The first dengue 
virus was taken from soldiers who became sick in Calcutta, New Guinea, and 
Hawaii.  
The virus is spherical and has an isometric core of 30-35 nm diameter. The 
nucleocapsid / core (c) protein is intricate with  single stranded RNA. This is 
enclosed by a lipid bilayer, which forms the covering & contains matrix 
/membrane (M) protein. The total span of the enveloped virus is 45-60nm. 
16,20,21 
The Dengue virus genome is 11,644 nucleotides in extent and has:  
1. Three structural protein genes which encodes the nucleocapsid core protein 
(C), a membrane – associated protein (M) and an envelope protein (E).16,20 
2. Seven non- structural protein (NS) genes – (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5)16,22,24 Among the non structural protein, envelope 
glycoprotein NS1, is 45 kDa in size and is connected with viral 
haemogglutination and neutralization activity.16 
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Functions of structural proteins: 
C Protein : It contributes to group activation and is detected by compliment 
fixation test and it is a 13 kDa protein. 
E Protein : It may help in anchoring of the virus to the host cell receptors. 
Antibody to E protein is protective and it is a glycoprotein.    
M Protein: Its function is to stabilize polymerization of E protein and  it has a 
molecular weight of 22 kDa. 
Functions of the Non –structural proteins :  
NS1 :  
A membrane bound glycoprotein and is expressed on virus infected cells and 
has replicative function. Antibodies to it are neither protective nor neutralizing. 
24,25 
NS3 :  
Acts as a virus specific protease along with NS2A. 24,25 
NS5 :  
 A virus polymerase as already mentioned , 4 serotypes of dengue present 
which all have common antigens but, vary in their ability to cause disease. 24,25  
Aedes aegypti and Aedes albopictus are the two significant vectors of dengue 16 
Vector: 
Aedes (stegomyia) aegypti:  
The Aedes (Stegomyia) aegypti (Ae. aegypti) mosquito which originates in 
Africa  exists as a feral Species and at  later stages, the species adapted to the 
peridomestic environment by breeding in water storage containers . Slave trade 
7 
 
and commerce with the rest of the world in the 17th to 19th centuries provided 
a mechanism for the species to be introduced to the “New World” and South-
East Asia.26 By 1800, the species spread to many large tropical coastal cities 
around the world. World War II provided yet another opportunity to the species 
for penetration into inland areas through the increased navigation by country 
boats on river systems. Increased transport, urbanization, human contact and 
the proliferation of drinking water supply schemes in rural areas ultimately led 
to the species getting spread in both urban and rural areas of most parts of the 
world. Because of high degree of domestication and strong affinity for human 
blood, it gets high vectorial capacity for transmission of DF/DHF . As per the 
distribution related records, Ae. aegypti present in most of the countries,where 
Ae. aegypti called as a cosmotropical species between latitudes 45°N and 
35°S.16 
Aedes (stegomyia) albopictus :  
Aedes (Stegomyia) albopictus belongs to the scutellaris group of subgenus 
Stegomyia, its an Asian species indigenous to South-East Asia and islands of 
the Western Pacific and the Indian Ocean,but during last few decades it spread 
to Africa , Europe,Americas (North and South) ,West Asia .The majority of the 
introductions are passive d/t transportation of dormant eggs through 
international shipments of used tyres. In newly infested countries  Ae. 
albopictus would cause serious outbreaks of arboviral diseases since Ae. 
albopictus is a competent vector of at least 22 arboviruses, notably dengue (all 
four serotypes), which is more commonly transmitted by Ae. aegypti.21 
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Vectorial competency 
Vectorial competency denotes: 
 Ability to replicate the virus. 
 High susceptibility to infecting virus. 
 Ability to transmit the virus to another host. 
Both Ae. aegypti and Ae. albopictus carry high vectorial competency for 
dengue viruses 
Vectorial capacity16 
Vectorial capacity is governed by the environmental and biological 
characteristics of the species. Ae. aegypti is a highly domesticated, strongly 
anthropophilic, nervous feeder (i.e. it bites more than one host to complete one 
blood meal) and is a discordant species (i.e. it needs more than one feed for the 
completion of the gonotropic cycle). These habits epidemiologically result in 
the generation of multiple cases and the clustering of dengue cases in cities. On 
the contrary, Ae. 
albopictus still maintains feral moorings and partly invades peripheral areas of 
urban cities, and thus feeds on both humans and animals. It is an aggressive 
feeder and a concordant species, i.e. the species can complete its blood meal in 
one go on one person and also does not require a second blood meal for the 
completion of the gonotropic cycle. Hence, Ae. albopictus carries poor 
vectorial capacity in an urban epidemic cycle. 
The common breeding sites for Aedes aegypti are domestic containers, 
ornamental containers, discarded receptacles, flower pots and roof gutters.20,21 
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The mosquito breeds and thrives during rainy and post rain seasons. A higher 
atmospheric temperature results in proliferation of the Aedes mosquitoes, as 
well as high humidity.16 
Their morphology includes black body with white stripes. They bite 
predominantly during morning and late afternoon hours. They predominantly 
lives indoors and are endophagic. They feed mostly on human blood 
(anthrophilic). The lifespan is around 1-4 weeks and eggs are not laid in 
clutches, which help in widespread dissemination and increased chance of 
survival and they withstand dessication for months. Transovarian transmission 
of the virus exists and this helps in maintenance during the interepidimic 
periods. 16,21 
Aedes species other than aegypti and albopticus transmitting dengue are Aedes 
polyneinsis, Aedes cooti and Aedes cutellans hebrideus.20  
Host :  
Dengue viruses have evolved from mosquitoes then  to non-human primates 
and then to humans in an evolutionary course. The viremia in  humans starts  
with elevated titres, 2 days prior to the beginning of the fever and lasts 5-8 days 
following  through the febrile phase. It is only during these two periods that the 
vector species gets infected,then the humans become dead-ends for 
transmission. The spread of infection occurs through the movement of the host 
(man) 
as the vectors’ movements are very restricted.The susceptibily of humans 
depends upon the immune status and genetic predisposition. Together monkeys 
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and humans are amplifying hosts and the virus is sustained by mosquitos 
transovarially by means of eggs.16 
Transmission cycle:  
It occurs in three different cycles.  
1. Enzootic cycle :  
A primitive sequence maintained by monkey- Aedes- monkey cycle is seen in 
South Asia and Africa where  virus is not pathogenic to the monkeys and all 4 
serotypes have been isolated  from monkeys.16,22 
2. Epizootic cycle :  
The dengue virus crosses over to non-human primates from neighboring human 
epidemics by vectors called bridge vectors was first identified in Sri Lanka 
during 1986-1987 among toque macaques which was proved by serological 
studies. 16 
3. Epidemic cycle :  
This cycle is maintained through human- Aedes – human cycle in episodic/ 
recurring epidemics. All serotype leads to hyperendemicity. In general Aedes 
aegypti has little inclination to oral infection by dengue virus but it’s really 
strong affinity towards human hosts (anthrophilic), multiple feeding tendencies 
and extremely domesticated habitats make it an competent vector.  
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Transmission of DF/ DHF:16,23  
Female Aedes mosquito bites human during viremic  
phase of illness  
 
Virus multiplies in the endothelial cell lining of the midgut of mosquito  
and then enters into hemocoele  
                                                    
Gains entry into the salivary glands and infects human through the saliva and genital tract 
also got infected and virus enters fully developed eggs during oviposition
The existrinsic incubation period  extends from 8-12 days then mosquitos will be  
infected till the end of it’s life. The Intrinsic Incubation Period  is from 5 to 7 days.16,23  
The Human Phase ;  
Following bite of an infected mosquito, virus multiplies in the local lymphnodes and in 
2-3 days spreads to the blood and various tissues. Virus circulates in the blood for five 
days. It also replicates in the splenic, skin, macrophages and lymphoid cells2 
Epidemiological Trends: 
Dengue is one of the rapidly spreading mosquito-borne viral disease in the world.For last 
5 decades, incidence has increased 30-fold with increasing distribution of geographic 
areas from urban to rural settings 
Some 1.8 billion  population at risk for dengue worldwide live in the WHO South-East 
Asia Region and Western Pacific Region,  in which it had 75% of global burden of 
disease. 27-30 
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Dengue in the WHO South-East Asia Region 
 In 2003, many countries in southeast asia reported dengue and in 2005,  
WHO’s 
Global Outbreak Alert and Response Network (GOARN) attended an outbreak 
in Timor leste with an high case fatality rate(3.55%)  .Nepal reported its first 
case on 2006.Only country in the southeast asia region has no reports of 
dengue. Cyclic epidemics are increasing in frequency & country geographic 
expansion  in Bangladesh, India and  Maldives  
Fig 3.1 Epidemics in the Southeast Asia regions according to WHO 
 
In most of regions case fatality rates are 1%, but in India, Indonesia and 
Myanmar, case-fatality rates of 3-5% had been reported. From January to 
September 2007, Myanmar reported  9578 cases, case-fatality rate in Myanmar 
is slightly above 1%.In June 2007, outbreaks was reported from Trat province, 
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Bangkok,Chiangrai, Phitsanulok, Khamkaeng Phet. A total of 58 836 cases was 
reported from January to November 2007 and case-fatality rate is below 0.2%. 
                Fig 3.2  Case fatality rate in SEARO regions according to WHO 
 
Dengue prevention and control will be implemented by the Bi-regional Dengue 
Strategy (2008--2015) This consists of six elements: 
 dengue surveillance,  
 integrated vector management, 
 case management, 
 outbreak response,  
 social mobilization and communication for dengue and  
 dengue research.  
Epidemiological trends in India:  
The dengue fever epidemiology is very complex in indian subcontinent32  
Dengue was first reported in India in 19467.The first evidence of dengue fever 
occurred at Vellore district in Tamilnadu in 195631.The first epidemic of 
dengue haemorrhagic fever takes place in Calcutta(West Bengal)in 1963 and 
then spread to Delhi by 19678 and it spreads to the whole country. Only 
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Lakshadweep, a union territory is not affected by dengue in India. The Kanpur 
epidemic in 1967 was due to DV-4 and in 196910 epidemic, both DV-2 and 4 
were isolated. The Vellore epidemic36,37 of 1966 was reported to be due to DV-
3 strain.DV-3 was also reported from Calcutta13 in 1983, Gwalior In 2003, 
2004 39,40and at Tirupur, Tamilnadu in 201041.  
Dengue has seasonal pattern, mostly during July-November an upsurge can be 
seen. But states in southern and western parts of country reporting perennial 
transmission.31 
The outbreaks in Delhi during 1996 reported 10252 cases and 423 deaths of 
total 16517 cases and 545 deaths in country31 .In 2003  due to DV-2 and DV-3 
strains in Delhi. DV-2 was the predominant serotype in Delhi until 2003,  then 
replaced by DV1 strain for next 3 years from 2007 to 2009. In 2006 with 12317 
cases and 184 deaths followed by 28292 cases in 2010 and 75808 in 2013. 
Case Fatality Ratio is 3.3% in 1996 declined to .3% in 2013.33,34.    The 
emergence of DV-4 with more severity  reported in Andhra Pradesh in 2007  
then Pune 2009 to 201021. 
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Fig 3.3 Average incidence rate of dengue in India 
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Table 3.1    Approximate number of Dengue cases & Death reported in 
201244 
 
 
 
 
 
 
 
 
Epidemiological trends in Tamilnadu 
In Tamil Nadu, there has been increase in  number of dengue cases during the 
last nine years. In 1998, dengue cases reported from the only 4 units but which 
was  increased to 33 units in 2006 due to the availability of recent lab 
adavances at many lab centers across the state . Almost in all districts of 
Tamilnadu dengue have been reported, of which outbreaks occur in mostly in 
Tiruppur, Coimbatore, Erode, Tiruvarur, Trichy, Krishnagiri, Dharmapuri, 
Nagercoil,  Ramanathapuram, have seen many outbreaks during last decade. In 
October 2001 and January 2002,  epidemic of dengue breakout  in Chennai, 
affect most of them including men and women mostly children's around 10 -15 
years of  age45.           
                                   
States, Union Territories No of Cases Deaths 
Tamilnadu 12826 66 
West Bengal 6456 11 
Kerala 4172 15 
Karnataka 3924 21 
Delhi 2093 04 
Puduchery 3506 05 
17 
 
Fig 3.4.Number of fever and dengue cases at Coimbatore medical college 
from daily newspaper “THE HINDU”. dated 10 october 2017. 
 
Immunopathogenesis: 46-57 
Viral Entry : 
 Flavivirus entry into the host cell is helped by numerous activities . The host 
cell has surface receptors which shows endocytic activity and trigger the 
signals for infiltration.  
 Flavirus get into the  host cell by coated vesicles &  transported into endosomes 
as this  happens in an acidic Ph (6.5), optimally.  
 
 Monocyte – macrophages are the important target cells for  Flavivirus.  
 The E-proteins in the virus in  connection to cells.  
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       Virus Replication:47 
 After entered into host cell through endosomes they are acidified and allow the 
nucleocapsid into the host cell cytoplasm and uncoating of genome occurs.  
 A  negative – strand intermediate which is a input strand translated to  becomes 
a template for the creation of multiple copies of positive – strand viral RNA 
(vRNA) , where it subsequently produces very high  levels of viral proteins.  
 This same process of translation produces multiple copies of structural protein 
capsid or core (C), envelope (E) proteins and premembrane (prM).  
Molecular basis of Immunopathogenesis: 46,49,50,51,52,53,54 
Many hypothesis for the pathogenesis of dengue virus infection have been 
stipulated but among the many hypothesis antibody dependent enhancement 
(ADE) of infection has  been understood to play a vital role.  
That proved with sera in DHF/DSS patients  were more likely to reveal ADE in 
vitro than with only DF.  
Effects of Dengue virus infection on Blood Cells: 46 
(1) Aberrant Immune Activation during dengue virus infection:  
(A) Inversion of CD4/CD8 ratio:  
 The  CD4/CD8 inversion was seen more  with DHF/DSS  than with DF.  
 CD4+ are in excess than CD8+ T cells in peripheral blood of normal persons. 
In patients with DHF/DSS CD8+ cells more that of CD4+ cells,hence ratio of 
CD4/CD8 cells declines to <1.  
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(B) Atypical lymphocytosis and Bandemia:  
 The  CD4 and CD8% monocytosis was higher  during day 6-7 in peripheral 
smear.  
 Aberrant immune activation   during dengue virus infection suggested  by the 
presence of atypical lymphocytes &  changes in  CD4/CD8 ratio 
 Bandemia means increased immature neutrophils  during days 5-6 after the 
onset of fever.  
 Atypical lymphocytosis reached the high on days 8-10 and then disappeared      
Fig 3.5  Antibody responses to dengue virus 
 
 
 
 
20 
 
2) Cytokine over production during Dengue virus Infection:  
 Elevated levels of cytokines in serum due to increased activation of 
mononuclear cells in acute infection.  
 Pro inflammatory markers include:   
 T-cell activation markers – soluble CD4, soluble CD8, IL-2, soluble IL - 2 
receptors , IFN.   
 Monokines – IFN , GM-CSF, TNF.  
These markers were  higher in DHF/DSS patients than  DF patients.  
 IL – 6 has  both  proinflammatory and an anti-inflammatory action.  
  IL-6 implies that  a host response to dengue virus infection by production of 
proinflammatory cytokines, but simultaneously there is also production of  the 
inhibitory cytokines to counter attack the inflammation.  
 Elevated levels of inhibitory cytokines – IL-10, soluble receptors of     sTNFR 
I, and sTNFR II  
 3)   Thrombocytopenia and Anti-platelet Antibodies:46,58,59 
Thrombocytopenia is more frequent  in DF and almost always found in     
DHF/DSS. The possible reasons of thrombocytopenia in dengue fever are:  
 Platelet destruction induced by DV antigen, gets attached to human platelets    
without any immune mediated reaction.  
 Dengue virus – induced bone marrow suppression which leading to low platelet 
synthesis and thrombocytopenia  
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 Anti-platelet autoantibodies  induced platelet destruction(mostly IgM) and it 
inhibits ADP-induced platelet aggregation but the affinity towards these auto 
antibodies is more increased  in secondary dengue infection 
 A modification in  endothelial cells by the infection of DV to the cell, may  
suggested the cause for thrombocytopenia. 58 
Dengue Virus – Induced Vasculopathy: 46,47 
 The most typical feature of DHF/DSS and the disease severity is plasma 
leakage  
 Plasma leakage is due to  false  increase in capillary permeability and presented 
as of hemoconcentration, pleural effusion, or ascites.  
 Plasma leakage occurs systemically, but resolves in 1-2days in patients after 
sufficient fluid resuscitation.  
  IL-6, IL-8 and RANTES they are most probably the causes of functional 
modification of endothelial cells. 
 In vivo studies that strain of DENV-2 have shows  destruction and apoptosis of 
endothelial cells 6(Strain PL 0046)  
 Endothelial cells infected by dengue virus are able to activate complement and 
expression of adhesion molecules such as ICAM-1 
 PMN and mononuclear cells increases attachment of virus to vascular 
endothelium and shows  increase in vascular permeability , thrombomodulin 
release.  
 Thrombomodulin is a marker of endothelial damage and its levels high in 
patients with DHF/DSS . 
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 Due to viral cytopathic effects, by leukocyte recruitment, the immune mediated 
endothelial damage produce and anti-dengue antibodies which produce 
structural injury to the  infected endothelial cells.  
 Endothelium plays a pivotal  role in function of  hemostasis, endothelial 
damage also result in procoagulant / anticoagulant discrepancies, sequestration 
of platelets by the activated endothelial cells amounting to thrombocytopenia 
will increase bleeding tendencies apart from plasma leakage  
Dengue Virus – Induced coagulopathy:46,50,51,52,54,55,56 
The pathogenesis of bleeding in DHF is unclear though disturbances exist.  
 Clinical manifestation ranges from a positive torniquet test, ecchymoses, skin 
petechiae to epistaxis , gum bleeding to severe gastrointestinal hemorrhage.  
 Hemorrhage results from these  mechanisms  
(i) Severe thrombocytopenia and associated with platelet dysfunction and the 
endothelial dysfunction  
(ii) Coagulopathy including DIC.  
(iii) Hemostasis is maintained  between coagulation and fibrinolysis.  
 Coagulation system - consists of intrinsic as well as extrinsic pathways.  
Activation of coagulation system leads to thrombin formation which converts 
Fibrinogen to  Fibrin then leads to formation of thrombus  
 Fibrinolytic system (facilitates fibrinolysis – clot lysis)  
Plasminogen is a proenzyeme activated by various types of  plasminogen 
activators  such as  tissue – type plasminogen activator (tPA).  
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Conversion of plasminogen to active plasmin enzyme and converts to  fibrin 
degradation products (FDP)   
 tPA is inhibited by plasminogen activator inhibitor 1(PAI-1), inhibits tPA  
synthesised in  liver, platelets and endothelium.  
 Coagulation activation triggers secondary activation of fibrinolysis  which 
stopped release  PAI – 1  
 Decreased PAI-1 secretion seen in acute dengue infection due to 
thrombocytopenia and altered liver functions which lead to a bleeding disorder.  
 Prolonged aPTT due to the defect in intrinsic coagulation pathway 
 Summarising the coagulation disorder in DHF/DSS,  
(i) Thrombocytopenia  
(ii) Endothelial Dysfunction  
(iii) Prolonged aPTT. 
(iv) Subnormal PAI-1 activity  
(v) Raised tPA activity 
Pathogenesis of liver dysfunction:46,47,60 
The clinical confirmation of liver involvement in dengue infections include the 
presence of hepatomegaly and augmented levels of liver enzymes. 
 In many studies there is a elevation of AST,ALT ,where it is elevated more in 
DHF,DSS.They return to normal values within 14-21 days. 
 Hepatic failure and fulminant hepatitis more frequent  in patients with 
DHF/DSS it  carries a poor prognosis. 57 
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 The AST increased more than ALP and AST levels more rapidly  than ALT 
levels  may be due to shorter half-life of AST . 57,60 
 In DF the histological changes are steatosis, Kupffer cell hyperplasia , 
hepatocellular necrosis,  Councilman bodies and cellular infiltrates at the portal 
tract.  
 Hepatocellular necrosis in DF mostly affect  the centrilobular and midzone 
areas,because these zones are most susceptible for anoxia or to products of 
immune response and dengue virus mostly infect these zones,as they infect 
boyh hepatocytes and kupffer cells but replication occurs in hepatocytes 
only.The destruction of hepatocytes is  due to involvement of dengue viruses 
which leads to apoptosis or immune mediated destruction 
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CLINICAL FEAUTRES 
Dengue infection is a systemic & dynamic disease.  
It is  a systemic disease has wide clinical spectrum 61. After the incubation 
period, the illness follows three phases -- febrile, critical  and recovery 
Febrile phase 
The febrile phase lasts 2-7 days and patients develop sudden fever followed by 
skin erythema, arthralgia, myalgia, headache and facial flushing, sore throat, 
conjunctival congestion, retroorbital headache. Anorexia, nausea and vomiting 
are common. It was difficult to distinguish between dengue and other non 
dengue febrile patients and also difficult to establish the differences between 
dengue and severe dengue with these symptoms in early febrile phase . A 
positive tourniquet test in this phase increases the probability of dengue 62,63.  
    Mild bleeding manifestations such as  petechiae and mucosal membrane 
bleeding Seen62,64. Massive vaginal bleeding (in women of childbearing age) 
and GI  bleeding may occur during this phase but uncommon64. Hepatomegaly 
can be present62 and decrease in total white cell count may be the earliest 
abnormality in hemogram. 
Critical phase 
In critical phase, usually the temperature drops to 37.5 to 38C, usually from 3-7 
days of illness and increase in haematocrit and increase capillary permeability 
occurs and a period of significant plasma leakage lasts 1-2 days. A decrease in 
platelet count which precedes by progressive leucopenia followed by plasma 
leakage. According to severity of plasma leakage the complications varies from 
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ascites, pleural effusion and finally the shock occurs when the critical volume 
of plasma leakage happens and with progression of shock hypoperfusion to the 
organ results in organ impairment, metabolic acidosis and DIC, as it leads to 
decreased hematocrit and severe haemorrhage results severe shock. Severe 
organ impairment as encephalitis, hepatitis, myocarditis. Those who deteriorate 
manifest as DWWS, Cases of dengue with warning signs will probably 
recover65,66 with early intravenous rehydration and some will deteriorate to 
SEVERE DENGUE 
Recovery phase 
     In recovery phases ,if patient persists 1-2 days in critical phase ,they can 
able to      alleviate all the complications in nect 2-3 days by gradual 
reabsortion of fluids,and hemodynamic status stabilizes ,haematocrit improves 
and ECG changes are common .But if if excessive fluid therapy given during 
recovery phase can be associated with pulmonary edema or CCF. 
Dengue without warning signs(DNWS) 
It mostly resembles that of febrile dengue phase, clinically it is quite 
conspicuous, which can be oligo symptomatic .The presence of confirmed 
cases in febrile patient’s environment is a determining factor for suspected 
clinical dengue diagnosis. 
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Fig 3.6 Different phases of dengue fever 
 
Dengue with warning signs(DWWS) 
 According to the DENCO study, intense abdominal pain,lethargy , mucosal 
bleeding, were the clinical manifestations of greatest  significance and were 
presented 24 hours before the severity of dengue starts68. 
Most of them are due to increased vascular permeability and indicates the 
starting of critical phase. signs are intense and persistent abdominal pain or 
tenderness. Its positive predictive value (PPV) was 90% clinically relevant 
plasma leakage such as ascites, pleural effusion,and 82% for shock,to a study 
of Salvadoran with dengue. frequent vomiting  had less PPV >3 in 1 hour or 4 
in 6 hours69.The intense abdominal pain referred to epigastrium d/t sudden 
presence of large amount of fluid in retroperitoneal region irritates nerve 
plexus72  which shows clear association b/w accumulation of fluid in 
retroperitoneal region and dengue shock. Gallbladder wall thickening d/t 
sudden plasma leakage in sufficient volume produce pain in  right upper 
quadrant, suggests a warning sign  
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Persistent vomiting.  
 >3 episodes in 1 hour or 4 in six hours. 
Persistent vomiting recognized as a clinical sign of severity73. In a study 
in Sinaloa, Mexico, persistent vomiting  with PPV (OR = 3.04; 95% CI = 1.05 
to 8.80) of severe disease. 
Fluid accumulation. 
    Manifest as  pleural effusion, ascites, or pericardial effusion74 and If 
hemodynamic compromise present, the patient classified as severe dengue 
case. 
Change in mental state. 
 Irritability  or drowsiness may occur, with a GCS of <15. Both 
manifestations are expression of cerebral hypoxia induced by  hypovolemia due 
to plasma leakage. 
Hepatomegaly. 
  Palpation of the liver > 2 cm below  costal margin. This due to  increase 
in liver’s size mostly due to congestion,  fatty metamorphosis ,intrahepatic 
hemorrhage. displacement of the liver from pleural effusion and ascites or 
retroperitoneal fluid accumulation71 
 Severe dengue 
Severe forms of dengue are defined by one or more of the following criteria: 
 shock or respiratory distress due to plasma leakage 
 bleeding  
 severe organ impairment (myocarditis, hepatitis, encephalitis) 
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15 If hypovolemia not corrected properly leads to increased capillary 
permeability and shock,which occurs mostly on 3-7 days .Dengue is a viral 
infection  which lipopolysaccharides don’t circulate, means that it doesn’t have 
a hot phase of shock as bacterial sepsis does. Shock is purely hypovolemic, at 
least in its initial phase. 
 It is useful with MAP to indicate the presence of hypotension; normal 
MAP is 70 to 95 mmHg. A MAP < 70 mmHg is considered hypotension.  
Shock is mostly seen in severe dengue and  produces uncontrolled 
leakage of fluids from  microvasculature, due to action of cytokines that induce 
apoptosis 75-77. It is one of the most pathological characteristic of dengue, 
differentiated from other viral infections and simultaneously there is decrease 
in platelet count. Thrombocytopenia in arbovirus due to adhered to  platelets 
and other megakaryocytic lineage cells and results in lysis.It is an 
immunologically mediated event d/t action of antibodies made against the 
proteins in the viral wall and turn into auto antibodies and cross react with 
platelet proteins, fibrinogen, and endothelium vascular proteins via molecular 
mimicry79,80.Moderate (<100,000 mm3) or severe (<10,000 mm3) 
thrombocytopenia can occur in dengue patients is transitionary, because the 
megakaryocytopoiesis  remains intact & hyperplastic during  critical phase of 
the disease71. But thrombocytopenia doesn’t determine shock, with increasing 
haematocrit and decrease in platelet count indicates disease severity. In severe 
dengue, abnormal coagulation profile seen, but not enough to cause severe 
bleeding. In severe dengue mostly they have coagulation abnormalities, but 
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usually they do not cause major bleeding, but when it occurs always associated 
with profound shock in associated with thrombocytopenia, it can also occur 
without shock in case of drug ingestion such as aspirin, brufen ,steroids. 
complications such as acute liver failure, encephalopathy, cardiomyopathy, 
encephalitis reported. 
Severe dengue suspected if the patient is from an area of dengue risk  with 
fever of 2–7 days with any of the following  signs 
There is evidence of plasma leakage, such as: 
 pleural effusions or ascites; 
 high or  rising haematocrit; 
 circulatory compromise or shock (cold and clammy extremities,CRT > 3 
seconds, tachycardia, weak  pulse,narrow pulse pressure or,  unrecordable 
blood pressure). 
• significant bleeding. 
• altered level of consciousness (lethargy or restlessness, convulsions, coma). 
•  severe gastrointestinal involvement (persistent vomiting, jaundice,  
intense abdominal pain). 
•  severe organ impairment (, acute renal failure, acute liver failure 
encephalopathy or encephalitis, cardiomyopathy) the case of fulminating 
hepatitis from dengue in which liver function is impaired leads to increase in 
aminotransferases, 10 times or more with elevation of prothrombin time (PT) 
which facilitates coagulation impairment. Based on its severity, hypoglycemia, 
hypoalbuminemia,and altered consciousness may be observed81,82. 
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Myocarditis  is mainly expressed by changes in heart rhythm Tachy and 
bradyarrhythmias , and T-wave and ST-segment inversion with ventricular 
dysfunction 83. seizures and changes in mental state are manifestations is 
central nervous system84,85. In dengue encephalitis,CSF can show presence of 
the virus / NS1 antigen/ IgM-specific antibodies76.  
However, most deaths from dengue occur in patients with severe shock (43), 
and pulmonary edema71 
     Fig 3.7 Classification of dengue fever according to WHO guidelines 
 
INVESTIGATIONS: 
Laboratory 
 Initial complete blood count: 
 A increase in hematocrit  
 A decreasing white blood cell count  
 A rapid decrease in platelet count 
 Additional tests to consider: 
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 liver function tests 
 blood glucose 
 serum urea and creatinine 
 arterial blood gases 
 Creatine kinase  
 Lipid profile 
 Lactate dehydrogenase 
 Albumin 
 Serum electrolytes 
 urinalysis 
 virus isolation / viral antigen /viral RNA by RT-PCR in blood.  
Then  IgM MAC-ELISA  most commonly used serological test for diagnosis of 
dengue; seroconversion or  increasing titre of specific dengue IgM or IgG in 
paired serum samples S/O  acute infection. IgM may be false positive in other 
flavivirides-JE, non flavivirides-malaria, leptospirosis, toxoplasmosis and 
syphilis, connective tissue disorders- rheumatoid arthritis, chronic liver disease.  
They maycomplicated due to the presence of flavivirus cross-reactivity .  Rapid 
diagnostic serological tests  but they also may not become positive until 
towards the end of the first week. ELISA test to identify circulating  
nonstructural 
protein88 (NS1 antigen) during the earlier part of  disease used for early 
diagnosis. 
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BIOMARKERS IN OUR STUDY 
Alterations in levels may caused by damage of  skeletal muscle in DHF 
patients, followed by increases in levels of LDH and CK.93,94 . liver damage is  
frequent problem in dengue that can  be associated with increased levels of 
LDH91,92. Levels of AST and ALT in patients with dengue were higher than 
with non-dengue febrile conditions. Plasma leakage, indicates that dengue 
causes hypoalbuminemia, indicator of severity.88-90 may be an early indicator of 
plasma leakage and useful prognostic marker. 
Low levels of triglycerides have been described in patients with severe 
dengue.In one study they evaluated 66 children with dengue showed lower 
triglyceride levels in DWWS patients with shock.92 Although  mechanism by 
which triglyceride levels changes has not been well established, this alteration 
can be explained by the interaction between lipids and free radicals, which are 
increased in patients with dengue. 
Fig 3.8 The course of dengue illness 
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Differential Diagnosis 
The differential diagnoses are leptospirosis, typhoid, malaria, Epstein-Barr 
virus, influenza, rickettsial infection, measles, rubella other arboviral infection. 
Treatment: 
 Keep patient hydrated orally. In oral intolerance, start IVF with 
crystalloid (RL or NS(0.9%) at dose maintenance:(2 to 4 mL/kg/hour) 
and restart oral route as soon as possible. 
 Reevaluate: if warning signs persist and urine output is <1 mL/kg/h, 
repeat load with isotonic crystalloids once or twice. 
Treatment of shock 
 initiate IVF with crystalloids (RL or 0.9%NS) at 20 mL/kg in 15 to 30 
min. 
 If signs of shock disappear, decrease to 10 mL/kg/hr; continue for 1 to 2 
hrs,then reduced to 5-7 ml/kg/hr,then 2-4 ml/kg/hr for 1-2 days 
 If there is no improvement, administer a second bolus  of solution at 20 
mL/kg in 15 to 30 min  
 If patient continues in shock, give colloid if still patient went for shock  
and the urgent need for cross-matching and transfusion of blood or 
blood products immediately. 
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Treatment of bleeding:   
Red blood cells  5-10 ml/kg or fresh blood at 10-20 ml/kg. THERE IS NO 
EVIDENCE TO SUPPORT THE USE OF PLATELET CONCENTRATE 
OR FFP OR CRYOPRECIPITATE WHATEVER BE THE SEVERITY 
OF THE BLEED. 
Criteria for clinical improvement 
 progressive disappearance of warning signs 
 good tolerance of oral route 
 stable vital signs 
 normal or increased urine output 
 reduction of  hematocrit 
 progressive remission of overall symptoms 
 recovery of appetite 
CRITERIA FOR DISCHARGE: 
 absence of fever > 48 hours, not with drugs 
 improvement of clinical status 
 good appetite 
 normal hemodynamic status 
 normal or increased urine output 
 no evidence of bleeding 
 increasing trend of platelet count 
 stable hematocrit without administration of intravenous fluids 
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Prevention of dengue fever: 
Control of Aedes aegypti by removing mosquito larvae from stagnant water 
sources is recommended .Aedes aegypti mosquitoes are daytime biters 
insecticide-treated bed nets  not much use. Avoidance of mosquito bites using 
mosquito repellents containing N, N-diethyl-3-methylbenzamide (DEET) / 
picaridin and protective clothing are most important preventive measures for 
traveller. 
Vector Management 
 Changes in human habitations 
 Personal protection 
 Biological control  
 Chemical control 
 Larvivorous fish can be grown in large water bodies or large containers 
 Endotoxin producing bacteria, Bacillus thuringiensis serotype H-14 can be used 
for the control of vector 
 Larvicides-   Temephos at a dose of 1 ppm  
 Adulticide- 
(a)Pyrethrum spray can  used in indoor situations 
 (b)Malathion fogging or Ultra Low Volume (ULV) spray is done  
Vector control: 
   Aedes aegypti is  primary vector of dengue virus. It is  day time feeder with 
peak biting periods being morning and  dusk in evening. There is  secondary 
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vector named Aedes alboptictus. Aedes ppolynesiensis, , Aedes furcifer Aedes 
scutellaris,  
Fig 3.9 Larva’s in a container 
 
Sampling of larvae and pupae 
House index (HI) 
It is  percentage of houses infested with larvae / pupae. 
HI = Infested houses / houses inspected  x 100 
Container index (CI) 
It is  percentage of water holding containers infested with larvae /pupae. 
CI = Containers positive / Containers inspected x 10 
Breteau index (BI) 
It is  number of positive containers /100 houses inspected. 
BI = number of positive containers / houses inspected X 100 
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Adult surveys 
 Landing / Biting collection 
 Resting collection 
 Oviposition traps 
RECENT ADVANCES IN TREATMENT OF DENGUE FEVER 
Herbal Treatment 
The Carica Papaya leaves are proposed to have therapeutic effects d/t many 
active components like papain chymopapain, glucosinolates cystatin, 
cyanogenic glucosides.They are antioxidants that reduce lipid peroxidation, and 
have antitumour activity and immunomodulatory effects. There are many 
studies  suggest that Carica Papaya Leaf Extract (CPLE) does significantly 
increases the platelet count in dengue patients 
Corticosteroids 
WHO don’t recommend steroids for the treatment of dengue fever. It is a 
matter of controversy 
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Antivirals 
Ribavirin, Glycyrrhizin and 6-Azauridine are reported   anti-dengue virus 
effect. No specific antiviral drugs available at present.  Adenosine analogues 
like NITD008 is one of the currently being studied drug. 
High dose IV immunoglobulin 
Recent studies suggest that  immune-mediated platelet destruction and 
vasculitis in dengue fever  caused by immune complexes. The  mechanism of 
action of IV Ig is not understood. 
Corticosteroids 
WHO don’t recommend steroids for the treatment of dengue fever. It is a 
matter of controversy. 
Monoclonal antibodies 
VIS513 is a monoclonal antibody that targets region on dengue virus. 
Preclinical studies have shown it neutralises all  4serotypes of dengue virus. 
DENGUE VACCINES IN CLINICAL DEVELOPMENT 
                                               Fig 3.10: Dengue Vaccine 
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Sanofi Pasteur’s CYD vaccine 
DENGVAXIA- It is a tetravalent  live attenuated vaccine which is 
administered subcutaneously. Trials are ongoing regarding the use of this 
vaccine.Vaccinatiation schedule consists of 3 injections of 0.5mlat 6 month 
intervals.  
TV003/ TV005 (NIAID) 
It is  developed by  National Institute of Allergy and Infectious Diseases by 
incorporating potential vaccine strains of  tetravalent dengue. 
TDENV PIV (GSK) 
It is a tetravalent purified inactivated vaccine under trials 
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METHODOLOGY 
 
                  The study is undertaken on the patients admitted in the Coimbatore 
Medical College and Hospital(CMCH), Coimbatore during the study period  of 
one year(July 2017 to June 2018). This study will be conducted as a 
prospective clinical study, where the written informed consent will be taken 
prior to  investigation after detailed information given to the participants about 
this study. Dengue fever patients will be screened for biochemical markers 
such as Creatinine kinase ,LDH,Total cholesterol, HDL, Triglycerides, SGOT, 
SGPT, Serum albumin through lab investigations and clinical signs and 
symptoms. 
Sample and sampling technique:  
Simple Random sampling technique in which sample size is calculated by 
following formula 
N = Z2 (1-α/2) x P x Q 
              d2 
Where, P is the known prevalence and Q =100-P 
Z = 1.96 (Value of Z at 5% α error) 
d = 20% of P 
Here P, the prevalence of dengue cases admitted in CMCH is 4 to 5% So, N = 
100 
So I studied 100 patients to compensate for the non- response cases. 
 Study design: prospective clinical study. 
 Set-up: CMCH Coimbatore. 
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 Study Period: 1 year study. 
 Age group: from 13 years. 
 All enumerated dengue patients in the age group from 13 years during the  
study period will be considered for the study. 
 Study type:one year prospective study. 
Selection Criteria 
Inclusion criteria  
1. Study participants more than 13 years of age. 
2. Acute febrile syndrome caused by dengue with duration of symptoms less 
than 5 days 
3. Cases fulfilling the WHO 2009 guidelines for dengue fever. 
PROCEDURE 
After getting permission from  IRB, patients was selected after explaining the 
purpose of study & procedure in detail and  getting their informed consent in 
written format. Consent was obtained from parents for patients who were 
minors. 
A detailed history of  illness taken, based on the WHO guidelines for diagnosis 
of  dengue fever. A complete physical examination and necessary 
investigations was done to confirm the diagnosis. 
DATA MANAGEMENT AND ANALYSIS 
Data was entered into MS Excel. 
 Statistical analysis was done using the software SPSS - Version 21. 
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RESULTS AND OBSERVATIONS 
Table 5.1: Age distribution of study subjects 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 30 65 65% 
31-45 22 22% 
46-60 7 7% 
>60 6 6% 
 
Chart 5.1: Age distribution of study subjects 
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Statistical analysis of Age distribution with types of dengue-NOT 
SIGNIFICANT 
Table 5.2 Age distribution with types of dengue 
TYPE OF DENGUE 
AGE IN YEARS 
MEAN SD 
DNWS 26.27 12.96 
DWWS 30.19 13.52 
SEVERE 33 20.71 
ANOVA 
P VALUE - 0.203 
NON SIGNIFICANT 
 
                             Chart 5.2 Age distribution with types of dengue 
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SEX 
Table 5.3: Distribution of study subjects according to sex 
SEX NO OF PATIENTS PERCENTAGE 
MALE 64 64% 
FEMALE 36 36% 
 
              Chart 5.3: Distribution of study subjects according to gender 
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Statistical analysis of sex distribution with types of dengue –NOT 
SIGNIFICANT 
Table5.4.Sex distribution with types of dengue 
TYPE OF DENGUE 
SEX 
MALE FEMALE 
DNWS 34 14 
DWWS 20 11 
SEVERE 10 11 
KRUSKAL WALLIS TEST 
P VALUE - 0.181 
NON SIGNIFICANT 
 
Chart 5.4.Sex distribution with types of dengue 
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DURATION OF FEVER 
Table 5.5 –Time duration of fever at the time of admission 
DURATION OF FEVER IN DAYS NO OF PATIENTS PERCENTAGE 
ONE 1 1% 
TWO 28 28% 
THREE 23 23% 
FOUR 25 25% 
FIVE 23 23% 
 
Chart 5.5 –Time duration of fever at the time of admission 
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Statistical analysis of time duration of fever at the time of admission  with 
types of dengue –NOT SIGNIFICANT  
Table5.6- Time duration of fever at the time of admission  with types of 
dengue 
DURATION OF FEVER IN DAYS 
TYPE OF DENGUE 
DNWS DWWS SEVERE 
ONE 1 0 0 
TWO 12 11 5 
THREE 13 5 5 
FOUR 13 5 7 
FIVE 9 10 4 
KRUSKAL WALLIS TEST 
P VALUE - 0.614 
NON SIGNIFICANT 
 
Chart5.6- Time duration of fever at the time of admission  with types of 
dengue
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LACTATE DEHYDROGENASE 
Table 5.7-Serum Lactate Dehydrogenase levels in dengue patients 
LACTATE DEHYDROGENASE NO OF PATIENTS PERCENTAGE 
HIGH 39 39% 
NORMAL 61 61% 
 
Chart 5.7-Serum Lactate Dehydrogenase levels in dengue patients 
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 Statistical analysis of Lactate dehydrogenase levels  with types of dengue – 
SIGNIFICANT especially more high in severe dengue patients and 
DWWS. 
Table- 5.8 Analysis of Lactate dehydrogenase levels  with types of dengue 
TYPE OF DENGUE 
LACTATE DEHYDROGENASE 
MEAN SD 
DNWS 148.45 11.81 
DWWS 219.32 30.74 
SEVERE 388.23 99.47 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.8 Analysis of Lactate dehydrogenase levels  with types of dengue
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CREATININE KINASE 
Table 5.9-Serum Creatinine kinase levels in dengue patients 
CREATININE KINASE NO OF PATIENTS PERCENTAGE 
HIGH 30 30% 
NORMAL 70 70% 
 
Chart 5.9-Serum Creatinine kinase levels in dengue patients 
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 Statistical analysis of Creatinine kinase levels  with types of dengue – 
SIGNIFICANT,especially more high in severe dengue patients and 
DWWS. 
Table- 5.10 Analysis of Creatinie kinase  levels  with types of dengue 
TYPE OF DENGUE CREATININE KINASE 
 
MEAN SD 
DNWS 169.22 22.17 
DWWS 233.48 64.3 
SEVERE 403.66 61.57 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
           
Chart- 5.10 Analysis of Creatinie kinase  levels  with types of dengue 
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TOTAL CHOLESTEROL  
           Table- 5.11 Serum Total cholesterol  levels  in dengue patients 
TOTAL CHOLESTEROL NO OF PATIENTS PERCENTAGE 
LOW 31 31% 
NORMAL 69 69% 
  
Chart- 5.11 Serum Total cholesterol  levels in  dengue patients 
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Statistical analysis of Total cholesterol levels  with types of dengue – 
SIGNIFICANT, especially more high(low levels) in severe dengue patients 
DWWS. 
Table- 5.12 Analysis of Total cholesterol  levels  with types of dengue 
TYPE OF DENGUE 
TOTAL CHOLESTEROL 
MEAN SD 
DNWS 178.02 9.04 
DWWS 157.35 28.64 
SEVERE 96.19 9.3 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
               
Chart- 5.12 Analysis of Total cholesterol  levels  with types of dengue 
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HIGH DENSITY LIPOPROTEIN 
Table- 5.13 Serum High Density Lipoprotein in dengue patients. 
HIGH DENSITY LIPOPROTEIN NO OF PATIENTS PERCENTAGE 
LOW 45 45% 
NORMAL 55 55% 
 
Chart- 5.13 Serum High Density Lipoprotein in dengue patients. 
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Statistical analysis of High density lipoprotein levels  with types of dengue 
– SIGNIFICANT, especially more high(low levels) in severe dengue 
patients and DWWS. 
Table- 5.14 Analysis of High density lipoproteins levels  with types of 
dengue 
TYPE OF DENGUE 
HIGH DENSITY LIPOPROTEIN 
MEAN SD 
DNWS 46.08 5.44 
DWWS 39.06 6.4 
SEVERE 31 4.2 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.14 Analysis of High density lipoproteins levels  with types of 
dengue 
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TRIGLYCERIDES 
Table- 5.15 Serum Triglycerides in dengue patients. 
TRIGLYCERIDES NO OF PATIENTS PERCENTAGE 
LOW 17 17% 
NORMAL 83 83% 
 
Chart- 5.15 Serum Triglycerides in dengue patients. 
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      Statistical analysis of Serum Triglycerides with types of dengue – 
SIGNIFICANT,especially more high(low levels) in severe dengue patients 
DWWS. 
Table- 5.16 Analysis of Serum Triglycerides with types of dengue 
TYPE OF DENGUE 
TRIGLYCERIDES 
MEAN SD 
DNWS 142.18 13.71 
DWWS 132.25 25.95 
SEVERE 94.66 7.93 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
         
Chart- 5.16 Analysis of Serum Triglycerides with types of dengue 
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SGOT 
Table- 5.17 Serum SGOT(Aspartate transaminase) in dengue patients. 
 
SGOT NO OF PATIENTS PERCENTAGE 
HIGH 55 55% 
NORMAL 45 45% 
 
Chart- 5.17 Serum SGOT(Aspartate transaminase) in dengue patients. 
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Statistical analysis of SGOT(Aspartate transaminase)  with types of 
dengue – SIGNIFICANT,especially more high(low levels) in severe dengue 
patients and DWWS. 
Table- 5.18 Analysis of SGOT(Aspartate transaminase) with types of 
dengue 
TYPE OF DENGUE 
SGOT 
MEAN SD 
DNWS 31.12 5.58 
DWWS 72.38 23.4 
SEVERE 137.95 51.66 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.18 Analysis of SGOT(Aspartate transaminase) with types of dengue 
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SGPT 
Table- 5.19 Serum SGPT(Alanine transaminase) in dengue patients. 
SGPT NO OF PATIENTS PERCENTAGE 
HIGH 51 51% 
NORMAL 49 49% 
 
Chart- 5.19 Serum SGPT(Alanine transaminase) in dengue patients. 
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Statistical analysis of SGPT(Alanine transaminase)  with types of dengue – 
SIGNIFICANT,especially more high(low levels) in severe dengue patients 
and DWWS. 
Table- 5.20 Analysis of SGPT(Alanine transaminase) with types of dengue 
TYPE OF DENGUE 
SGPT 
MEAN SD 
DNWS 31.08 5.94 
DWWS 75.16 28.42 
SEVERE 135 50.57 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.20 Analysis of SGPT(Alanine transaminase) with types of dengue 
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                                             SERUM ALBUMIN 
Table- 5.21 Serum  Albumin in dengue patients. 
SERUM ALBUMIN NO OF PATIENTS PERCENTAGE 
LOW 36 36% 
NORMAL 64 64% 
 
Chart- 5.21 Serum  Albumin in dengue patients. 
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Statistical analysis of Serum Albumin with types of dengue – 
SIGNIFICANT especially more high(low levels) in severe dengue patients 
and DWWS 
Table- 5.22 Analysis of Serum Albumin  with types of dengue 
TYPE OF DENGUE 
SERUM ALBUMIN 
MEAN SD 
DNWS 4.55 0.48 
DWWS 3.55 0.46 
SEVERE 3.02 0.28 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.22 Analysis of Serum Albumin   with types of dengue 
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TYPE OF DENGUE 
Table 5.23 Number of dengue patients according to types   
TYPE OF DENGUE NO OF PATIENTS PERCENTAGE 
WITHOUT WARNING SIGNS(DNWS) 48 48% 
WITH WARNING SIGNS(DWWS) 31 38% 
SEVERE DENGUE(SD) 21 21% 
 
Chart 5.23 Number of dengue patients according to types   
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COMPLICATIONS 
Table- 5.24 Presence or absence of complications in dengue patients. 
COMPLICATIONS NO OF PATIENTS PERCENTAGE 
PRESENT 52 52% 
ABSENT 48 48% 
 
Chart- 5.24 Presence or absence of complications in dengue patients. 
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Statistical analysis of Presence or absence of complications with types of 
dengue –   SIGNIFICANT, more in Severe Dengue and DWWS 
Table- 5.25 Analysis of Presence or absence of complications with types of 
dengue 
TYPE OF DENGUE 
COMPLICATIONS 
PRESENT ABSENT 
DNWS 0 48 
DWWS 31 0 
SEVERE 21 0 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
Chart- 5.25 Analysis of Presence or absence of complications with types of 
dengue 
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BLOOD TRANSFUSION 
Table- 5.26 Blood transfusions given  in dengue patients. 
BLOOD TRANSFUSION NO OF PATIENTS PERCENTAGE 
YES 29 29% 
NO 71 71% 
 
Chart- 5.26  Blood transfusions given  in dengue patients. 
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Statistical analysis of Blood Transfusions given with types of dengue –  
NOT SIGNIFICANT 
Table- 5.27 Analysis of Blood Transfusions given with types of dengue 
TYPE OF DENGUE 
BLOOD TRANSFUSION 
YES NO 
DNWS 0 48 
DWWS 15 16 
SEVERE 14 7 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
NON SIGNIFICANT 
 
Chart- 5.27 Analysis of Blood Transfusions given with types of dengue 
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DEATH 
Table- 5.28 Number of deaths in dengue patients. 
 
DEATH NO OF PATIENTS PERCENTAGE 
YES 9 9% 
NO 91 91% 
 
Chart- 5.28 Number of deaths  in dengue patients. 
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Statistical analysis of Number of deaths  with types of dengue –  
SIGNIFICANT,in Severe Dengue  
Table- 5.29 Analysis of Number of deaths  with types of dengue 
TYPE OF DENGUE 
DEATH 
YES NO 
DNWS 0 48 
DWWS 0 31 
SEVERE 9 12 
ANOVA 
P VALUE - 0.001 
 SIGNIFICANT 
 
Chart- 5.29 Statistical analysis of Number of deaths and their association 
with types of dengue 
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CAUSE OF DEATH 
Table 5.30 Causes of death in dengue patients 
DEATH (N=9) NO OF PATIENTS PERCENTAGE 
ENCHEPHALITIS 5 55% 
SEVERE BLEEDING 2 23% 
RESPIRATORY FAILURE 2 23% 
 
Chart 5.30 Causes of death in dengue patients 
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DISCUSSION 
 
      A total of 100 cases were included in this study. Of these 65 cases were less 
than 30 years, 22 cases were 31-45 years,7 cases were 46-60 years, and the 
remaining 6 cases were older than 60 years which shows most of cases were 
between age group <30 years. Males constitute about 64 cases and females 36 
cases with an Male: Female ratio of 1.7:1 with male preponderance. According 
to the WHO guidelines 2009 ,patients were classified on the basis of severity 
were,48 patients in DNWS,31 patients in DWWS,19 patients in SD.Depending 
upon the duration of fever at the time of admission 1day-1,2days-28,3days-
23,4days-25,5days-23.In these patients with the biochemical markers can able 
to suggest whether which patients are more progress severe dengue. 
          Lactate dehydrogenase(LDH) has 5 isoforms,normal value is 115-
221 U/L,39 patients had high levels,remaining normal.Mean value for LDH in 
Severe dengue is 388.23 and SD is 99.47,with P value <0.001 by ANOVA test 
shows significant association with severe dengue and DWWS. 
Creatinine Kinase has 3 isoforms of normal value 51-294 U/L with 30 
patients had high values, remaining normal. mean value of 403.66 in severe 
dengue and SD is 61.57, with P value <0.001 by ANOVA test shows 
significant association with severe dengue and DWWS. 
Total cholesterol normal value is < 200mg/dl,31 patients with low value 
,remaining normal,with mean value of 96.19 in severe dengue with SD 9.3, 
with P value <0.001 by ANOVA test shows significant association with severe 
dengue and DWWS. 
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High density lipoprotein normal value is 40- 59 mg/dl,45 patients had 
low value,remaining normal, with mean value of 31 in severe dengue and SD 
of 4.2, with P value <0.001 by ANOVA test shows significant association with 
severe dengue and DWWS. 
Triglycerides of normal value <150 mg/dl,17 patients with low value, 
remaining normal, with mean value of 94.66 in severe dengue and SD of 7.93, 
with P value <0.001 by ANOVA test shows significant association with severe 
dengue and DWWS. 
SGOT(Aspartate Transaminase) of normal value of 12-38 U/L, of which 
55 patients had high value ,remaining normal. Mean value in severe dengue is 
137.95 and SD is 51.66 , with P value <0.001 by ANOVA test shows 
significant association with severe dengue and DWWS. 
SGPT(Alanine Transaminase) of normal value of 7-41 U/L,of which 51 
patients had high value remaining normal. Mean value of 135 in severe dengue 
and SD is 50.57, with P value <0.001 by ANOVA test shows significant 
association with severe dengue and DWWS. 
Serum Albumin of normal value of 3.5-5.5 g/dl,36 patients had low 
values. Mean value of 3.02 in Severe dengue and SD of 0.28, with P value 
<0.001 by ANOVA test shows significant association with severe dengue and 
DWWS. 
Of these 100 patients ,29 were given blood transfusion and it is not significant 
with severe dengue by Kruskal wallis test.52 patients presented with various 
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complications of dengue fever which shows significant association with severe 
dengue by Kruskal wallis test. 
Total number of deaths is 9 among 100 patients.These 9 patients are in 
severe dengue group and the cause of death is encephalitis in 5 patients ,severe 
bleeding in 2 patients and respiratory failure in 2 patients . 
Remaining patients in a severe dengue group had complications such as 
ICH,Retroorbital haemorrhage,Septic arthritis and consolidation in lung fields. 
In DWWS group patients had complications such as pleural effusion, 
minimal ascites, proptosis eye,hepatomegaly, persistent vomiting ,mucosal 
bleeding,polyserositis,etc 
3 patients were pregnant had persistent vomiting in DWWS  group of 7 
to 8 months amenorrhea each of them 
Of these 100 patients ,55 patients are from Coimbatore district,31 
patients from Tiruppur district,remaining from erode ,dindigul,ooty districts 
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SUMMARY 
 
 Dengue Fever is causing epidemics in different parts of India. 
 Biochemical markers in Dengue Fever is usually overlooked, especially in 
peripheral hospitals. 
 In this study the correlation between biochemical alterations and  progression 
of probable dengue →dengue with warning signs →Severe dengue in adults 
studied 
 100 patients admitted with confirmed Dengue Fever were study subjects. 
 Age range of patients was >13 years. 
 Out of 100 patients studied 64 were males and 36 females 
 Patient had a h/o disease such as diabetes, AIDS, Hematologic disorders, 
cancer and with already having severe dengue and their complications  
 The study subjects were divided into three groups based on WHO guidelines 
2009, 
            DNWS - 48 patients,  
            DWWS -31 patients,  
            SD - 19 patients 
 Among 100 subjects ,9 were dead ,in severe dengue group mostly due to 
encephalitis, severe bleeding,ARDS, respiratory failure 
 Of 100 patients ,29 were given blood transfusion and 52 of them presented with 
some of the complications of dengue fever 
 3 patients were pregnant during the study of 7 to 8 months amenorrhea 
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• Most of them are belong to Coimbatore district then Tiruppur, Ooty, Erode 
,Dindigul districts. 
• These are the areas are having high endemecity of dengue fever and prevention 
and destroying the larva’s in containers are very minimal. 
• Almost all patients in severe dengue had complications and some patients in 
DWWS had complications 
• They had complications such as persistent vomiting, increase in haematocrit, 
hepatomegaly, mucosal bleeding, ARDS, sepsis, Renal failure, seizures etc 
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CONCLUSIONS 
 
As this study and statistics  points out that there is a significant association with 
biomarkers such as CK, LDH, CHOLESTEROL, HDL, TRIGLYCERIDES, 
SERUM ALBUMIN , SGOT & SGPT, and also it clearly states that they are 
significantly raised in DWWS and SD rather than in DNWS, so, with these 
biomarkers we can able to suspect that which patients who are more prone to 
go for DWWS & SD, as that patients under careful supervision and 
management can able to prevent them from progressing to severe dengue. High 
values of CREATININE KINASE ,LACTATE DEHYDROGENASE 
,ASPARTATE TRANSAMINASE and  ALANINE TRANSAMINASES & 
Reduced levels of CHOLESTEROL ,HIGH DENSITY LIPOPROTEIN, 
TRIGLYCERIDES and SERUM ALBUMIN  As Early alterations of  these 
biochemical markers can predict progressing to SEVERE DENGUE  in 
patients with acute fever caused by dengue 
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LIMITATIONS 
• This study was conducted in a tertiary care centre where referral bias cannot be 
avoided. 
• Nutritional factors which may explain the mechanism of serum triglycerides 
with severity of dengue, and their dietary habits and nutritional aspects has not 
been evaluated in this study. 
• Antibody titres were not quantitated. 
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95. GUIDELINES FOR PATIENT CARE IN THE REGION OF THE 
AMERICAS Second edition 
 
  
PROFORMA 
 
Name: 
Age:          
Sex:        
I.P.No:  
DOA: 
Symptoms: 
Fever:                      Days:                     Days prior to admission:               
High/Low 
Continuous/Intermittent                        Chills: 
Headache:                                             Days:                                            Area: 
Retro orbital Pain:                                 Myalgia:                                       
Arthralgia: 
Hemorrhagic manifestations: 
Epistaxis/ malena/ Gum bleed/ Hematemesis/ Vena.Punc.Bleed/ Hess Test/                 
Rashes(area: )  other- menorrhagia, prolonged bleed 
Abdominal Pain:                            Nause/Vomiting:                       
Constip/Diarrhea: 
Coryza:                                             Sleep/Lethargy:  
Past h/o fever 
BP 
Pulse rate: 
Temp; <39/>390 :          
Pallor:                                               Face\flush: 
Conj.Injection:                                     Lyphadenopathy:  
Systemic examination 
Laboratory Investigations: 
TC            DC-N             DC-L          DC - E          PCV            HB                
Platelet 
BT            CT          Sugar             Urea            Creatinine        S.Bil             
SGOT 
SGPT       SAP        T.Protein         S.Alb          CK                  LDH 
CHOLESTEROL                       HDL                    TRIGLYCERIDES 
Dengue Test IgM:                      IgG: 
CXR 
USG Abdomen: 
Blood transfusion: 
Dengue :Infection                          Type: Primary secondary  
Dengue Type: DNWS                    DWWS                           SD 
Outcome: 
 
 
 
 
 
 
 
 
åŠ¹î™ ð®õ‹ 
 
 
 
ªðò˜   :   
 
õò¶   :    
 
ð£Lù‹  : 
 
ºèõK  : 
 
 
 
 
 
 
 
«è£¬õ Üó² ñ¼ˆ¶õ‚ è™ÖK ñ¼ˆ¶õñ¬ùJ™ ñ¼.k.tre;jd; î¬ô¬ñJ™ 
ï¬ìªðÁ‹ Þ‰î ÝŒM™ âù¶ º¿àì™ ñŸÁ‹ ÞóˆîŠ ðK«ê£î¬ù ªêŒ¶ ªè£œ÷ º¿ 
ñù¶ì¡ ê‹ñF‚A«ø¡. â¡¬ùŠ ðŸPò Mõóƒè¬÷ ð£¶è£Š¹ì¡ Þ‰î ÝŒM™ ªõOJì 
Ý†«êð¬í Þ™¬ô â¡Á ªîKMˆ¶‚ ªè£œA«ø¡. ï£¡ â‰î «ïóˆF½‹ ÝŒM™ Þ¼‰¶ 
Mô‚A‚ ªè£œÀ‹ àK¬ñ à‡´ â¡Á ÜP«õ¡. 
 
 
 
 
 
Þì‹        ¬èªò£Šð‹/¬è«ó¬è 
 
«îF 
 
 
 
  
KEY TO MASTER CHART 
 Age ( in years) 
 Sex 
           1-Male 
           2- Female  
 Location of patient(Residence) 
 Duration of fever at the time of admission 
 LDH 
 CK 
 Total Cholesterol 
 HDL 
 Triglycerides 
 SGOT 
 SGPT 
 Serum albumin 
 DNWS 
              0 - Absent 
              1 – Present 
 DWWS         
              0 - Absent 
              1 – Present 
 
 
 SEVERE DENGUE 
              0 - Absent 
              1 – Present 
 Complications 
 Blood transfusions 
               0 - Absent 
               1 – Present 
 Death 
               0 - Absent 
               1 – Present 
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1 PARVATHY 28 2 ERODE 4 145 240 170 45 113 30 30 4 1 0 0 NIL 0 0
2 SARADHA 34 2 CBE 5 148 150 175 50 114 34 22 4.5 1 0 0 NIL 0 0
3 SURYAPRAKASH 17 1 DINDIGUL 3 138 138 180 55 145 38 23 4.8 1 0 0 NIL 0 0
4 RAJ 50 1 ERODE 2 156 146 185 41 148 42 34 4.2 1 0 0 NIL 0 0
5 PAUL 17 1 CBE 3 135 152 190 43 138 32 25 5 1 0 0 NIL 0 0
6 MANJULA 36 2 CBE 4 148 154 195 45 156 36 29 5.1 1 0 0 NIL 0 0
7 MANIKANDAN 16 1 CBE 5 136 158 150 47 135 40 31 4.9 1 0 0 NIL 0 0
8 SNEHA 14 2 TIRUPPUR 2 133 158 155 49 148 30 33 4.8 1 0 0 NIL 0 0
9 KARPAGAM 40 2 CBE 3 151 170 160 51 136 22 35 4.7 1 0 0 NIL 0 0
10 VIGNESH 14 1 CBE 4 134 130 165 53 133 23 37 5.1 1 0 0 NIL 0 0
11 JEGANRAJ 20 1 TIRUPPUR 5 136 136 170 55 151 34 39 5.3 1 0 0 NIL 0 0
12 MANIKANDAN 17 1 TIRUPPUR 1 137 139 175 42 134 25 21 3.9 1 0 0 NIL 0 0
13 SRIPATHI 18 1 TIRUPPUR 2 123 212 180 44 136 29 23 3.8 1 0 0 NIL 0 0
14 KARUPPUSAMY 15 1 CBE 3 145 180 172 46 137 31 25 4 1 0 0 NIL 0 0
15 MANIBALAN 17 1 CBE 4 133 135 174 48 123 33 27 4.3 1 0 0 NIL 0 0
16 VIMALA 32 2 TIRUPUR 5 145 157 176 50 145 35 29 4.6 1 0 0 NIL 0 0
17 BIKASH NAYAN 29 1 CBE 2 136 184 178 52 133 37 31 4.9 1 0 0 NIL 0 0
18 RAVI 26 1 TIRUPPUR 3 147 158 180 54 145 39 33 4 1 0 0 NIL 0 0
19 VEERANAN 30 1 TIRUPPUR 4 142 189 182 56 136 21 35 4.2 1 0 0 NIL 0 0
20 PRADEEP 23 1 CBE 5 135 196 184 38 147 23 37 4.4 1 0 0 NIL 0 0
21 SASIKALA 29 2 TIRUPPUR 2 136 199 186 37 142 25 39 4.6 1 0 0 NIL 0 0
22 CHANDRU 29 1 ERODE 3 138 177 188 39 135 27 22 4.8 1 0 0 NIL 0 0
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23 MUTHURAMALINGAM 65 1 CBE 2 136 188 190 38 136 29 24 5 1 0 0 NIL 0 0
24 DURGAPPAN 25 1 TIRUPPUR 4 163 185 170 40 138 31 26 5.2 1 0 0 NIL 0 0
25 RAJU 33 1 CBE 2 154 184 172 41 136 33 28 5.1 1 0 0 NIL 0 0
26 FEROZ 29 1 CBE 3 137 145 176 43 125 35 30 3.8 1 0 0 NIL 0 0
27 DHIVYA 19 2 TIRUPPUR 4 139 167 178 44 127 37 32 3.9 1 0 0 NIL 0 0
28 ANGELINE MARY 13 2 CBE 5 145 174 190 45 128 39 34 4 1 0 0 NIL 0 0
29 SRI MURUGAN 35 1 CBE 2 148 189 178 46 135 22 36 4.2 1 0 0 NIL 0 0
30 SARAN 16 1 CBE 3 149 158 180 50 136 24 38 4.4 1 0 0 NIL 0 0
31 SANKARAN 13 1 TIRUPPUR 4 136 177 177 51 163 26 40 4.7 1 0 0 NIL 0 0
32 PAKKAR 17 1 TIRUPPUR 5 135 189 178 55 154 28 31 4.9 1 0 0 NIL 0 0
33 SWATHY 17 2 CBE 2 137 165 180 54 137 30 33 4.1 1 0 0 NIL 0 0
34 RAJESH KUMAR 34 1 CBE 3 138 155 174 53 139 32 35 4.3 1 0 0 NIL 0 0
35 SARASWATHY 42 2 DINDUGAL 4 178 178 176 52 145 34 37 4.9 1 0 0 NIL 0 0
36 ANGUSAMHY 18 1 CBE 5 154 195 178 41 148 36 39 3.8 1 0 0 NIL 0 0
37 DILRAJ 18 1 TIRUPPUR 2 166 146 180 42 149 30 21 3.6 1 0 0 NIL 0 0
38 RAJASEKAR 13 1 CBE 3 157 179 182 43 136 22 23 5.4 1 0 0 NIL 0 0
39 SIVABALAN 14 1 TIRUPPUR 4 154 166 184 44 135 23 24 5.2 1 0 0 NIL 0 0
40 PRADEEP KUMAR 25 1 CBE 3 166 178 186 45 137 34 26 5 1 0 0 NIL 0 0
41 SELVARAJ 49 1 DINDUGAL 2 163 195 188 46 138 25 28 5 1 0 0 NIL 0 0
42 BHEEM 22 1 TIRUPPUR 3 154 164 190 39 178 29 30 5.2 1 0 0 NIL 0 0
43 BHOJAN 67 1 OOTY 4 137 179 188 38 154 31 35 4.5 1 0 0 NIL 0 0
44 MANIYAL 13 2 TIRUPPUR 5 139 180 190 40 166 33 40 4.9 1 0 0 NIL 0 0
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45 PRAVEENA 23 2 CBE 2 145 186 170 41 157 35 45 4.5 1 0 0 NIL 0 0
46 VISWAS 14 1 CBE 3 148 174 172 44 154 37 30 4.7 1 0 0 NIL 0 0
47 SARASWATHI 42 2 DINDIGUL 4 178 135 172 50 178 34 35 4.1 1 0 0 NIL 0 0
48 SELVARAJ 34 1 CBE 4 149 134 176 47 166 39 32 4.2 1 0 0 NIL 0 0
49 LATHIKA 14 2 CBE 4 345 356 95 26 101 147 66 3 0 0 1 DEATH-ENCEPHALITIS 1 1
50 MURUGESAN 75 1 CBE 4 453 478 92 28 102 230 78 3.2 0 0 1 DEATH-ENCEPHALITIS 1 1
51 SIVARAMAN 17 1 CBE 5 388 383 93 30 96 201 80 2.8 0 0 1 DEATH-RESPIRATORY FAILURE 1 1
52 CHELLAMMAL 85 2 CBE 2 340 365 94 31 95 188 134 2.7 0 0 1 DEATH-SEVERE BLEEDING 1 1
53 MALAR 33 2 CBE 3 325 375 96 33 95 174 155 2.5 0 0 1 DEATH-ENCEPHALITIS 1 1
54 VANISHREE 23 2 TIRUPPUR 4 347 354 97 35 92 155 196 2.4 0 0 1 DEATH-RESPIRATORY FAILURE 1 1
55 PRIYA 25 2 TIRUPPUR 5 389 477 90 37 93 176 134 2.8 0 0 1 DEATH-ENCEPHALITIS 1 1
56 AROCKIAMARY 40 2 CBE 2 679 499 93 26 94 187 144 2.9 0 0 1 DEATH-SEVERE BLEEDING 1 1
57 OTHIBAS 45 1 TIRUPPUR 3 547 525 95 29 96 111 166 3 0 0 1 DEATH-ENCEPHALITIS 1 1
58 INBASELVAN 18 1 TIRUPPUR 4 330 323 93 30 97 102 147 3.2 0 0 1 ENCEPHALITIS 0 0
59 GOPIKRISHNA 24 1 ERODE 5 340 489 70 31 90 66 230 3.4 0 0 1SEPTIC ARTHRITIS RIGHT KNEE/SEPTIC SHOCK1 0
60 PRAVEENA 23 2 TIRUPPUR 5 335 348 90 23 93 78 201 3 0 0 1RT ML CONSOLIDATION/RESPIRATORY FAILURE1 0
61 RANJITH KUMAR 22 1 CBE 3 467 356 92 26 93 134 174 2.9 0 0 1 LT PARIETAL ICH 1 0
62 VIMALRAJ 13 1 TIRUPPUR 4 307 368 94 28 70 155 155 3 0 0 1 ENCEPHALITIS 0 0
63 DHIVYA 19 2 TIRUPPUR 4 485 362 95 29 90 196 176 3.5 0 0 1 ENCEPHALITIS 0 0
64 MAHALAKSHMI 75 2 CBE 3 502 378 113 36 116 70 78 3.3 0 0 1 RETROBULBAR HAEMORRHAGE 1 0
65 VINITHA 20 2 CBE 2 367 342 99 30 91 134 187 3.4 0 0 1 ARDS ON VENTILATOR 0 0
66 JEYAKUMAR 36 1 TIRUPPUR 3 299 378 102 33 94 166 102 3.2 0 0 1 ENCEPHALITIS 0 0
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67 SETTU 31 1 KARUR 2 304 408 105 35 95 85 98 3.2 0 0 1 ARDS ON VENTILATOR 0 0
68 RAKESH KUMAR 25 1 TIRUPPUR 2 306 427 106 37 99 96 76 3.1 0 0 1 ARDS 0 0
69 MINACH PARVEEN 30 2 CBE 4 298 486 116 38 96 46 58 3 0 0 1 ENCEPHALITIS 1 0
70 PERIYAKKA 21 2 DINDIGUL 5 223 246 119 32 102 52 68 4 0 1 0 7MA- VOMITING 0 0
71 MEENA 22 2 CBE 4 226 235 115 34 105 68 88 3.5 0 1 0 8MA-VOMITING 1 0
72 PARVATHY 22 2 CBE 3 275 201 133 36 106 69 98 4.2 0 1 0 8MA-VOMITING 1 0
73 GOPALDINGAL 53 1 TIRUPPUR 2 268 322 96 32 92 144 111 3.3 0 1 0 RT MODERATE PLEURAL EFFUSION 1 0
74 JAYAKUMAR 36 1 CBE 2 235 267 134 33 119 70 58 3.4 0 1 0 MUCOSAL  BLEED 1 0
75 MANIKANDAN 23 1 TIRUPPUR 5 254 274 132 36 115 45 86 3.5 0 1 0 PROPTOSIS LT EYE 1 0
76 PALANISAMY 47 1 CBE 2 267 345 124 36 133 48 77 3.4 0 1 0 UGI BLEED 1 0
77 JAYAPRIYA 32 2 CBE 2 243 279 111 34 113 90 76 3.2 0 1 0 VOMITING 0 0
78 VELUSAMY 65 1 CBE 3 224 265 113 35 134 93 97 3.6 0 1 0 SEPSIS 1 0
79 APPUSAMY 47 1 ERODE 5 254 278 124 32 132 64 85 3 0 1 0 HEPATOMEGALY 1 0
80 THULASIAMMAL 55 2 CBE 2 231 289 176 35 124 88 96 3.3 0 1 0 HCT INCREASE 0 0
81 SINGAMUTHU 49 1 CBE 2 242 368 187 37 111 56 46 3.4 0 1 0 POLYSEROSITIS 0 0
82 SUJITH KUMAR 22 1 CBE 4 221 321 168 38 113 63 52 3 0 1 0 SEPSIS 1 0
83 IRKA SALIMA 29 2 CBE 5 224 189 170 36 124 66 68 3.4 0 1 0 MUCOSAL BLEEDING 1 0
84 RAJU 33 1 CBE 3 257 188 169 38 132 68 69 3 0 1 0 SEPSIS 1 0
85 ANGUSAMY 18 1 CBE 5 235 150 170 34 101 78 70 3.7 0 1 0 HCT INCREASE 0 0
86 DURGAPPAN 25 1 TIRUPPUR 4 188 138 175 35 103 98 70 3.8 0 1 0 HEPATOMEGALY 0 0
87 SATHYA 18 2 TIRUPPUR 5 198 146 180 40 143 76 45 3.9 0 1 0 POLYSEROSITIS 0 0
88 MOHAMMED JAVED 15 1 CBE 2 178 209 185 42 144 58 48 3.5 0 1 0 MUCOSAL BLEEDING 1 0
SL
. N
O
N
A
M
E 
A
G
E
SE
X
LO
C
A
TI
O
N
D
U
R
A
TI
O
N
LD
H
(1
15
-2
21
U
/l)
C
K
(M
=5
1-
29
4U
/L
,F
=3
9-
23
8U
/L
)
C
H
O
LE
ST
ER
O
L(
<2
00
 m
g/
dl
)
H
D
L(
40
-5
9m
g/
dl
) 
TG
L(
30
-1
50
m
g/
dl
)
SG
O
T(
12
-3
8U
/L
)
SG
PT
(7
-4
1U
/L
)
A
LB
U
M
IN
(3
.5
-5
.5
g/
dl
)
D
N
W
S
D
W
W
S
SE
V
ER
E 
D
EN
G
U
E
C
O
M
PL
IC
A
TI
O
N
S
BL
O
O
D
  T
R
A
N
SF
U
SI
O
N
D
EA
TH
89 JAYANTHI 40 2 DINDIGUL 2 199 265 190 46 145 68 90 3.2 0 1 0 VOMITING 0 0
90 FEROZ 29 1 CBE 4 201 274 195 48 156 88 93 3.3 0 1 0 HEPATOMEGALY 0 0
91 ANJELINE MARY 13 2 CBE 5 223 213 150 43 166 98 64 3.5 0 1 0 POSTURAL HYPOTENSION 0 0
92 SRIMURUGAN 35 1 CBE 2 226 235 155 42 176 78 88 3.4 0 1 0 POLYSEROSITIS 0 0
93 SARAN 16 1 CBE 3 187 241 160 44 184 58 56 3.4 0 1 0 HCT INCREASE 0 0
94 SANKARAN 13 1 CBE 4 179 271 165 46 173 86 63 3.5 0 1 0 MUCOSAL BLEEDING 1 0
95 PAKKAR 17 1 TIRUPPUR 5 168 139 170 47 145 77 66 3.4 0 1 0 HEPATOMEGALY 0 0
96 SWATHY 18 2 TIRUPPUR 2 178 212 175 48 178 76 68 3.9 0 1 0 POLYSEROSITIS 0 0
97 SAJINA BEGUM 24 1 CBE 5 188 125 178 48 143 21 35 4.8 0 1 0 POLYSEROSITIS 0 0
98 ABUTHAHIR 37 1 CBE 2 179 137 190 50 147 23 33 4.9 0 1 0 MUCOSAL BLEEDING 1 0
99 GEETHA 28 2 CBE 5 240 236 189 25 95 80 188 2.8 0 1 0 B/L PNEUMONITIS SEPSIS 1 0
100 RAJESH KUMAR 34 1 CBE 3 188 180 180 49 146 97 78 4 0 1 0 VOMITING 0 0
